The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
Yung‐Chang Chen(University of Electronic Science and Technology of China), Tong-Yu Lin(University of Electronic Science and Technology of China), Yanhong Deng(Sun Yat-sen University), Huawei Weng(Sun Yat-sen University), Mengmeng Wu(Nankai University), Xue Wu(Hangzhou Normal University), E Mingyan(Harbin Medical University), Qiuxiang Ou(Genesee Community College), Xingxiang Pu(Central South University), Hao Sun(Southeast University), Xinggui Chen(Guangdong Medical College), Yang Liu(Shanxi Medical University), Hongyu Zhang(Dongguan People’s Hospital), Yaru Zhang, Sheng Ye(Shanghai University), He Huang(Peking University), Yutong Ma, Hongqiang Guo(Zhengzhou University), Anxin Gu(Harbin Medical University), Yang Shao(Sanya University), Chaoyong Liang(Guangxi Medical University), Chunman Wu
Cited by 17
Related Papers
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410